Cognitive disorders

Global Dementia Epidemiology and Patient Flow Analysis & Forecasts 2020-2035 - ResearchAndMarkets.com

Monday, May 10, 2021 - 9:44am

b'The "Global Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Dementia Epidemiology and Patient Flow Analysis - 2021, provides Dementia epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Dementia Epidemiology and Patient Flow Analysis - 2021, provides Dementia epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Dementia patients, history of the disease at the population level (Dementia prevalence, Dementia incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Dementia patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Dementia market sizing, assessing market potential, and developing drug forecast models\nIdentify Dementia patients segments through age groups, gender, and disease sub-types\n'

2021 Global Lewy Body Dementia Epidemiology and Patient Flow Report - ResearchAndMarkets.com

Friday, May 7, 2021 - 2:44pm

b'The "Global Lewy Body Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Lewy Body Dementia Epidemiology and Patient Flow Analysis - 2021, provides Lewy Body Dementia epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Lewy Body Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Lewy Body Dementia Epidemiology and Patient Flow Analysis - 2021, provides Lewy Body Dementia epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Lewy Body Dementia patients, history of the disease at the population level (Lewy Body Dementia prevalence, Lewy Body Dementia incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nLewy Body Dementia patient flow: Lewy Body Dementia prevalence, diagnosed, and drug-treated patients\nDemographics: Lewy Body Dementia patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Lewy Body Dementia market sizing, assessing market potential, and developing drug forecast models\nIdentify Lewy Body Dementia patients segments through age groups, gender, and disease sub-types\nEvaluate Lewy Body Dementia market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210507005374/en/\n'

Karuna Therapeutics Reports First Quarter 2021 Financial Results and Provides General Business Update

Thursday, May 6, 2021 - 11:30am

KarXT is currently being evaluated as a potential treatment for psychiatric disorders, including schizophrenia and dementia-related psychosis.\nKarXT for the treatment of psychosis in adults with schizophrenia.

Key Points: 
  • KarXT is currently being evaluated as a potential treatment for psychiatric disorders, including schizophrenia and dementia-related psychosis.\nKarXT for the treatment of psychosis in adults with schizophrenia.
  • 10,933,020 and 10,925,832 related to compositions and methods for treating disorders ameliorated by muscarinic receptor activation.\nCOVID-19 update.
  • Our actual results could differ materially from the results described in or implied by such forward looking statements.
  • Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.\n"

Memore Launches Functional Whole Food Blends for Sustainable Cognitive Health

Tuesday, May 4, 2021 - 1:00pm

b'CHARLOTTE, N.C., May 4, 2021 /PRNewswire/ --Today, Memore [pronounced "memory"], a new direct-to-consumer brand, launches functional whole food blends that offer a convenient and versatile way to improve cognitive performance.

Key Points: 
  • b'CHARLOTTE, N.C., May 4, 2021 /PRNewswire/ --Today, Memore [pronounced "memory"], a new direct-to-consumer brand, launches functional whole food blends that offer a convenient and versatile way to improve cognitive performance.
  • Founded by husband-wife duo Brad and Erika Lepczyk, Memore carves out an important place in the consumer space for sustainable cognitive health solutions.\nEach Memore pouch contains 30 servings of brain-boosting nutrients thanks to high-quality ingredients derived from 11 whole foods and three plant-based protein sources.
  • Memore products are loaded with whole food ingredients, including brain-boosters like blueberry, spinach, sweet potato and beet.
  • To learn more, please visit www.yourmemore.com and follow @yourmemore on Instagram and Facebook .\nFounded in 2021, Memore is a company dedicated to sustainable cognitive health that offers functional blends that conveniently fill gaps in your diet with whole food nutrition shown to improve cognition, slow cognitive decline and reduce your risks of Alzheimer\'s dementia.

Yumanity Therapeutics to Host Virtual R&D Day on Monday, May 17, 2021

Tuesday, May 4, 2021 - 1:00pm

b'BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that the Company will host a virtual R&D Day on Monday, May 17, 2021 at 12:00 p.m.

Key Points: 
  • b'BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that the Company will host a virtual R&D Day on Monday, May 17, 2021 at 12:00 p.m.
  • The Company\xe2\x80\x99s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\xe2\x80\x99s disease.
  • Yumanity\xe2\x80\x99s drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases.
  • Yumanity\xe2\x80\x99s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig\xe2\x80\x99s disease), frontotemporal lobar dementia (FTLD), and Alzheimer\xe2\x80\x99s disease.

Tombot, creator of the first affordable, FDA-regulated medical robotic animal, is now accepting investors

Monday, May 3, 2021 - 10:30pm

Tombot conducted three rounds of consumer studies with 100s of seniors with dementia during product design.

Key Points: 
  • Tombot conducted three rounds of consumer studies with 100s of seniors with dementia during product design.
  • Tombot\'s research showed seniors strongly prefer robotic animals with realistic appearance and behaviors.\nTombot\'s Co-founder and CEO, Tom Stevens, founded the company based upon his mother Nancy Stevens\' personal battle with Alzheimer\'s dementia.
  • We\'re focusing on the needs of one patient at a time and making sure we can provide them with the necessary medical benefits.
  • You can learn more about Tombot and invest through their offering page here .\n'

IG Wealth Management Walk for Alzheimer's Unites Canadians Virtually this May

Monday, May 3, 2021 - 5:07pm

b'TORONTO, May 3, 2021 /CNW/ - Canadians will come together to celebrate the 2021 IG Wealth Management Walk for Alzheimer\'s on May 30th.

Key Points: 
  • b'TORONTO, May 3, 2021 /CNW/ - Canadians will come together to celebrate the 2021 IG Wealth Management Walk for Alzheimer\'s on May 30th.
  • The IG Wealth Management Walk for Alzheimer\'s is Canada\'s biggest fundraiser in direct support of the more than half a million Canadians living with dementia.\nWhile the pandemic negatively impacted so many services across the country last year, Canadians came together to participate in the first ever virtual walk, raising more than $5.1 million dollars.
  • "Our clients and their caregivers count on Canadians to walk for their loved ones and raise crucial funds to fight dementia.
  • IG Wealth Management has nearly $107 billion in assets under management as of March 31 2021 and is a member of the IGM Financial Inc. (TSX: IGM) group of companies.

Passage Bio Partners with InformedDNA® to Offer Genetic Counseling and Testing for Patients with Frontotemporal Dementia (FTD), a Form of Early Onset Dementia

Monday, May 3, 2021 - 12:00pm

FTD is a debilitating form of early onset dementia that currently has no approved disease-modifying therapies.

Key Points: 
  • FTD is a debilitating form of early onset dementia that currently has no approved disease-modifying therapies.
  • \xe2\x80\x9cBy partnering with InformedDNA, we are able to offer patients with FTD an option to potentially identify whether there is an inherited genetic mutation causing their disease.
  • Individuals will receive initial and post-test genetic counseling over the phone from InformedDNA genetic counselors who are highly trained in hereditary neurological conditions.
  • Key offerings include clinical genetic counseling, genetic testing utilization management, genetic testing payment integrity , and expert genetics support for clinical trials .

Yumanity Therapeutics to Present at the 2021 B. Riley Securities’ Neuroscience Conference

Thursday, April 29, 2021 - 1:07am

The Company\xe2\x80\x99s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\xe2\x80\x99s disease.

Key Points: 
  • The Company\xe2\x80\x99s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\xe2\x80\x99s disease.
  • Yumanity\xe2\x80\x99s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases.
  • Yumanity\xe2\x80\x99s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig\xe2\x80\x99s disease), frontotemporal lobar dementia (FTLD), and Alzheimer\xe2\x80\x99s disease.
  • For more information, please visit www.yumanity.com .\n"

Evon Medics, LLC Has Been Awarded $2.5 Million Grant for the Evaluation of its Medical Device for the Treatment of Alzheimer's Disease

Thursday, April 29, 2021 - 1:31pm

"I believe the COT can effectively bridge the treatment gap and will be a delight to all Alzheimer\'s Disease patients who suffer from the numerous side effects of the currently available palliative treatments for AD.

Key Points: 
  • "I believe the COT can effectively bridge the treatment gap and will be a delight to all Alzheimer\'s Disease patients who suffer from the numerous side effects of the currently available palliative treatments for AD.
  • The pilot study showed very encouraging results and I am confident of similar results for the pivotal study we are about to embark on.
  • "\nEvon Medics, LLC is a medical devices and neuroscience research company founded in April 2013 by Johns Hopkins trained physicians.
  • The company develops therapeutics and devices for the treatment of Alzheimer\'s Disease, Opioid Use Disorder, Traumatic Brain Injury, Chronic pain, Treatment Refractory Depression, and other chronic neurological diseases that have remained elusive to treatment.